Apr 22 2025
More on Rebalancing Therapy: Suppressing Protein S
Click here for your copy of The World Federation of Hemophilia Shared Decision-making Tool, Hemostatic Rebalancing Therapy. We’ve posted several entries about rebalancing therapy… Pfizer’s Hympavzi® (marstacimab) Anti-TFPI Approved Hemophilia Therapeutics Discontinued Fitusiran Approved March 28, 2025 Fitusiran: A “Rebalancing Agent” Concizumab, A “Rebalancing Agent” August 2024 Quick Question Summary: Rebalancing Therapy Alhemo® (concizumab) Rebalancing […]
read more